| 000 | 01525 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250518013203.0 | ||
| 264 | 0 | _c20190304 | |
| 008 | 201903s 0 0 eng d | ||
| 022 | _a1573-7225 | ||
| 024 | 7 |
_a10.1007/s10552-018-1117-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMayer, Sophie E | |
| 245 | 0 | 0 |
_aCYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. _h[electronic resource] |
| 260 |
_bCancer causes & control : CCC _cJan 2019 |
||
| 300 |
_a103-112 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2D6 _xgenetics |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP2D6 Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Recurrence, Local |
| 650 | 0 | 4 | _aPhenotype |
| 650 | 0 | 4 |
_aTamoxifen _xtherapeutic use |
| 700 | 1 | _aWeiss, Noel S | |
| 700 | 1 | _aChubak, Jessica | |
| 700 | 1 | _aDoody, David R | |
| 700 | 1 | _aCarlson, Christopher S | |
| 700 | 1 | _aMakar, Karen W | |
| 700 | 1 | _aWurscher, Michelle A | |
| 700 | 1 | _aMalone, Kathleen E | |
| 773 | 0 |
_tCancer causes & control : CCC _gvol. 30 _gno. 1 _gp. 103-112 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10552-018-1117-x _zAvailable from publisher's website |
| 999 |
_c29156035 _d29156035 |
||